Mike Hollan

The Boehringer Ingelheim leader discusses his leadership style and how it impacts his team’s strategy.

Noah Nasser discusses the importance of keeping data still.

With insured patients less likely to benefit, who actually does benefit from D2C?

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new treatments.

Derrick Gastineau discusses how the focus on weight loss medications has shifted in recent years.

Michael Grosberg discusses how people with insurance will be impacted by D2C drug sales.

A joint statement lays out the framework for a potential trade agreement.

Staff members published an open letter to the HHS Secretary following a deadly shooting earlier this month.

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.

Powering learnings of the dark genome to tackle disease at its source.

Pushing for access wins in quickly evolving market and digital health landscapes.

Ex-Wall Street trader is helping reshape how patients receive biologics.

A mission leader in next-generation pursuits around targeted therapy.

Pioneer of cell-reset technology steers science-to-startup transformation.

The comments came after the AAP announced its vaccine recommendations, which go against those of the CDC.

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

The EMD Serono president discusses his new role and goals for the company.

EVERSANA’s Alan Crowther discusses how pharma can prepare for the impact of the order.

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

The AeroRx Therapeutics CEO discusses new treatments and how the industry at large is reacting to them.

The latest decision will give Vanda the opportunity to have a hearing with FDA over the sNDA’s status.

The order aims to set US drug prices at the same level as the lowest cost in other markets.

The Google Cloud director discusses AI implementation and workflow.

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing drug prices.

The federally created panel was previously disbanded in 1998.

The new list price will bring the medication in line with other European markets.

Sources say the President’s focus has shifted.

Users find themselves suddenly looking for an extra $500-a-month in their budgets.

Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in dollars charged to the state’s Medicaid program.